Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.69 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16264688 | 0.85 | GRM5 (0.61) | GRM5ASIC3KDM4EKMT2AMEN1 | |
| SCHEMBL5582608 | 0.82 | GRM5 (1.00) | GRM5ASIC3HTTKMT2AMEN1 | |
| SCHEMBL5582696 | 0.77 | GRM5 (1.00) | GRM5ASIC3 | |
| SCHEMBL5582909 | 0.72 | GRM5 (1.00) | GRM5ASIC3 | |
| SCHEMBL27311239 | 0.71 | SLC2A1 (0.50) | KDM4EKMT2AMEN1PDE10AALDH1A1 | |
| SCHEMBL5582626 | 0.70 | GRM5 (1.00) | GRM5ASIC3 | |
| SCHEMBL21666863 | 0.70 | RAB9A (0.59) | KDM4EKMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL15779673 | 0.70 | SLC2A1 (0.56) | KDM4EHTTKMT2AMEN1PDE10A | |
| SCHEMBL29533207 | 0.70 | BTK (0.46) | KDM4EKMT2AMEN1 | |
| SCHEMBL20260151 | 0.69 | GRM5 (0.61) | GRM5ASIC3HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| WO-2005021529-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | GRM5 1/4885ASIC3 366/4885KDM4E 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.